Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
HIGH POINT, N.C. , July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019 , and provided an update on recent achievements and upcoming events. “We made significant progress during the second quarter,”
View HTML
Toggle Summary vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 15, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral
View HTML
Toggle Summary vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 27, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes.
View HTML
Toggle Summary vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 6, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the
View HTML
Toggle Summary vTv Therapeutics Announces 2019 First Quarter Financial Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--May 1, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019 , and provided an update on recent achievements and upcoming events. “We continue to make significant progress with our operational
View HTML
Toggle Summary vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
Presentation of Results for Subgroup of Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the STEADFAST Study HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of
View HTML
Toggle Summary vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 18, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase
View HTML
Toggle Summary vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018 , and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential
View HTML
Toggle Summary vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational
View HTML
Toggle Summary vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30 th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City .
View HTML